SM
NVAX icon

Skaana Management’s Novavax NVAX Stock Holding History

Skaana Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-119,000
Closed -$800K – 159
2025
Q4 		$800K Buy
119,000
+100
+0.1% +$754 0.26% 60
2025
Q3 		$1.03M Hold
118,900
– – 0.29% 56
2025
Q2 		$749K Hold
118,900
– – 0.23% 60
2025
Q1 		$762K Sell
118,900
-192,900
-62% -$1.59M 0.28% 51
2024
Q4 		$2.51M Buy
311,800
+30,200
+11% +$291K 0.64% 33
2024
Q3 		$3.56M Buy
281,600
+187,700
+200% +$2.42M 0.86% 24
2024
Q2 		$1.19M Buy
93,900
+64,900
+224% +$653K 0.36% 54
2024
Q1 		$25.8M Sell
29,000
-296,000
-91% -$1.37M 0.51% 30
2023
Q4 		$1.56M Buy
325,000
+278,200
+594% +$1.7M 0.28% 53
2023
Q3 		$339K Sell
46,800
-30,700
-40% -$245K 0.08% 89
2023
Q2 		$576K Sell
77,500
-436,500
-85% -$3.43M 0.13% 81
2023
Q1 		$3.56M Buy
514,000
+303,900
+145% +$2.8M 1.09% 25
2022
Q4 		$2.16M Buy
+210,100
New +$3.71M 0.47% 41

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Skaana Management's NVAX Position: Q1 2026 in Review

Skaana Management sold out of Novavax (NVAX) in Q1 2026, closing a stake of 68,300 shares — an estimated $459K sold.

Skaana Management first reported a position in NVAX in Q2 2023 and held it in 9 quarters. The position peaked at $4.22M in Q3 2024. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Skaana Management reported no remaining Novavax position as of Q1 2026 after selling out during the quarter.
  • Skaana Management sold 68,300 Novavax shares in Q1 2026, an estimated $459K.
  • Skaana Management first reported a position in Novavax in Q2 2023 and held it in 9 quarters.
  • Skaana Management's Novavax position peaked at $4.22M in Q3 2024.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Skaana Management's 13F filing for Q1 2026, filed 11 May 2026.